Citation: | HE Wenchao, ZHU Mucheng, SU Quanbin, ZHANG Qi, ZENG Wenbao, YAO Siqi, ZHANG Zhengyi. A study on clinical characteristics and prognostic factors of HFpEF patients using ARNI based on latent class analysis[J]. Chinese Journal of General Practice, 2025, 23(1): 59-64. doi: 10.16766/j.cnki.issn.1674-4152.003835 |
[1] |
中华医学会心血管病学分会, 中国医师协会心血管内科医师分会, 中国医师协会心力衰竭专业委员会, 等. 中国心力衰竭诊断和治疗指南2024[J]. 中华心血管病杂志, 2024, 52(3): 235-275.
Chinese Medical Association Branch of Cardiology, Chinese Medical Doctor Association Branch of Cardiovascular Physicians, Chinese Medical Doctor Association Heart failure professional Committee, et al. Chinese guidelines for the diagnosis and treatment of heart failure 2024[J]. Chinese Journal of Cardiology, 2024, 52(3): 235-275.
|
[2] |
射血分数保留的心力衰竭诊断与治疗中国专家共识制定工作组, 周京敏, 杨杰孚, 等. 射血分数保留的心力衰竭诊断与治疗中国专家共识2023[J]. 中国循环杂志, 2023, 38(4): 375-393. doi: 10.3969/j.issn.1000-3614.2023.04.001
Chinese Expert Consensus Working Group on Diagnosis and Treatment of Heart Failure With Preserved Ejection Fraction, ZHOU J M, YANG J F, et al. Diagnosis and Treatment of Heart Failure With Preserved Ejection Fraction: Chinese Expert Consensus 2023[J]. Chinese Circulation Journal, 2023, 38(4): 375-393. doi: 10.3969/j.issn.1000-3614.2023.04.001
|
[3] |
VADUGANATHAN M, MENTZ R J, CLAGGETT B L, et al. Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF[J]. Eur Heart J, 2023, 44(31): 2982-2993. doi: 10.1093/eurheartj/ehad344
|
[4] |
GE J. Coding proposal on phenotyping heart failure with preserved ejection fraction: a practical tool for facilitating etiology-oriented therapy[J]. Cardiol J, 2020, 27(1): 97-98. doi: 10.5603/CJ.2020.0023
|
[5] |
方理刚. 射血分数保留的心力衰竭的分类及诊断[J]. 临床内科杂志, 2020, 37(7): 463-466. doi: 10.3969/j.issn.1001-9057.2020.07.001
FANG L G. Classification and diagnose of heart failure with preserved ejection fraction[J]. Journal of Clinical Internal Medicine, 2020, 37(7): 463-466. doi: 10.3969/j.issn.1001-9057.2020.07.001
|
[6] |
NAKON O, UTRIYAPRASIT K, WANITKUN N, et al. The effect of health literacy on health status in patients with heart failure: a path analysis[J]. J Multidiscip Healthc, 2024, 17: 4143-4153. doi: 10.2147/JMDH.S472860
|
[7] |
SOLOMON S D, MCMURRAY J J V, ANAND I S, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction[J]. N Engl J Med, 2019, 381(17): 1609-1620. doi: 10.1056/NEJMoa1908655
|
[8] |
SANDERS W E J R, BURTON T, KHOSOUSI A, et al. Machine learning: at the heart of failure diagnosis[J]. Curr Opin Cardiol, 2021, 36(2): 227-233. doi: 10.1097/HCO.0000000000000833
|
[9] |
PRAUSMÜLLER S, HEITZINGER G, PAVO N, et al. Malnutrition outweighs the effect of the obesity paradox[J]. J Cachexia Sarcopenia Muscle, 2022, 13(3): 1477-1486. doi: 10.1002/jcsm.12980
|
[10] |
郦心瑶, 高亚宇, 李鑫琪, 等. 老年射血分数保留型心力衰竭与衰弱的相关性研究进展[J]. 中国当代医药, 2024, 31(12): 180-184. doi: 10.3969/j.issn.1674-4721.2024.12.043
LI X Y, GAO Y Y, LI X Q, et al. Research progress on correlation of heart failure with preserved ejection fraction and frailty in the elderly[J]. China Modern Medicine, 2024, 31(12): 180-184. doi: 10.3969/j.issn.1674-4721.2024.12.043
|
[11] |
姜苏蓉, 曹雅茹, 王璎瑛, 等. 25-羟维生素D缺乏与老年射血分数保留心力衰竭的相关性研究[J]. 中华全科医学, 2021, 19(11): 1815-1818, 1835. doi: 10.16766/j.cnki.issn.1674-4152.002174
JIANG S R, CAO Y R, WANG Y Y, et al. Correlation between 25-hydroxyvitamin D deficiency and heart failure with preserved ejection fraction in the elderly[J]. Chinese Journal of General Practice, 2021, 19(11): 1815-1818, 1835. doi: 10.16766/j.cnki.issn.1674-4152.002174
|
[12] |
LI M, WEI N, SHI H Y, et al. Prevalence and clinical implications of polypharmacy and potentially inappropriate medication in elderly patients with heart failure: results of six months' follow-up[J]. J Geriatr Cardiol, 2023, 20(7): 495-508. doi: 10.26599/1671-5411.2023.07.002
|
[13] |
MILLER D D. Machine intelligence in cardiovascular medicine[J]. Cardiol Rev, 2020, 28(2): 53-64. doi: 10.1097/CRD.0000000000000294
|
[14] |
朱鸣雷, 刘晓红, 董碧蓉, 等. 老年共病管理中国专家共识(2023)[J]. 中国临床保健杂志, 2023, 26(5): 577-584. doi: 10.3969/J.issn.1672-6790.2023.05.001
ZHU M L, LIU X H, DONG B R, et al. Chinese expert consensus on management of elderly patients with multimorbidity(2023)[J]. Chinese Journal of Clinical Healthcare, 2023, 26(5): 577-584. doi: 10.3969/J.issn.1672-6790.2023.05.001
|
[15] |
DOMINGUEZ L J, DONAT-VARGAS C, SAYON-OREA C, et al. Rationale of the association between Mediterranean diet and the risk of frailty in older adults and systematic review and meta-analysis[J]. Exp Gerontol, 2023, 177: 112180. DOI: 10.1016/j.exger.2023.112180.
|
[16] |
UIJL A, SAVARESE G, VAARTJES I, et al. Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction[J]. Eur J Heart Fail, 2021, 23(6): 973-982. doi: 10.1002/ejhf.2169
|
[17] |
GAN L, LYU X, YANG X, et al. Application of angiotensin receptor-neprilysin inhibitor in chronic kidney disease patients: Chinese Expert Consensus[J]. Front Med(Lausanne), 2022, 9: 877237. DOI: 10.3389/fmed.2022.877237.
|
[18] |
金士琪. 基于多参数磁共振定量监测慢性肾病心肌损伤及经ARNI治疗前后的影像学评价研究[D]. 沈阳: 中国医科大学, 2023.
JIN S Q. Quantitative monitoring and evaluation of myocardial injury in chronic kidney disease and the changing of ARNI treatment based on multiparameter magnetic resonance imaging[D]. Shenyang: China Medical University, 2023.
|
[19] |
CHANG H Y, LIN C C, CHAO C J, et al. Real-world experience of angiotensin receptor-neprilysin inhibition in reduced ejection fraction heart failure patients with advanced kidney disease[J]. Mayo Clin Proc, 2023, 98(1): 88-99. doi: 10.1016/j.mayocp.2022.06.007
|
[20] |
BORLAUG B A, SHARMA K, SHAH S J, et al. Heart failure with preserved ejection fraction: JACC Scientific Statement[J]. J Am Coll Cardiol, 2023, 81(18): 1810-1834. doi: 10.1016/j.jacc.2023.01.049
|
[21] |
BARILLI M, TAVERA M C, VALENTE S, et al. Structural and hemodynamic changes of the right ventricle in PH-HFpEF[J]. Int J Mol Sci, 2022, 23(9): 4554. DOI: 10.3390/ijms23094554.
|
[22] |
VAN WEZENBEEK J, KIANZAD A, VAN DE BOVENKAMP A, et al. Right ventricular and right atrial function are less compromised in pulmonary hypertension secondary to heart failure with preserved ejection fraction: a comparison with pulmonary arterial hypertension with similar pressure overload[J]. Circ Heart Fail, 2022, 15(2): e008726. DOI: 10.1161/CIRCHEARTFAILURE.121.008726.
|
[23] |
LIANG W L, LIANG B. Soluble guanylate cyclase activators and stimulators in patients with heart failure[J]. Curr Cardiol Rep, 2023, 25(6): 607-613. doi: 10.1007/s11886-023-01884-9
|
[24] |
AL-OMARY M S, SUGITO S, BOYLE A J, et al. Pulmonary hypertension due to left heart disease: diagnosis, pathophysiology, and therapy[J]. Hypertension, 2020, 75(6): 1397-1408. doi: 10.1161/HYPERTENSIONAHA.119.14330
|
[25] |
DE SIMONE V, GUARISE P, ZANOTTO G, et al. Reduction in pulmonary artery pressures with use of sacubitril/valsartan[J]. J Cardiol Cases, 2019, 20(5): 187-190. doi: 10.1016/j.jccase.2019.08.006
|